Fosamax and Osteonecrosis of the Jaw: Scientific Evidence and Risk Context

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Medication Risks

The legacy domain of general health and science information has long provided a foundation for public understanding of disease prevention, treatment options, and medication safety. Within this broad context, discussions of pharmaceutical benefits and risks have typically emphasized therapeutic outcomes and population-level health impacts. As the focus narrows from general health awareness to specific medication exposures, a critical transition occurs: the shift from abstract risk communication to concrete occupational and environmental hazard assessment. This pivot is particularly relevant when examining bisphosphonate therapies such as Fosamax, which have been associated with rare but serious adverse events like osteonecrosis of the jaw. In occupational settings, healthcare workers, pharmaceutical manufacturing personnel, and dental professionals may encounter heightened exposure scenarios—whether through handling, administration, or patient care. The transition from general health literacy to occupational exposure concern requires acknowledging that medication-related risks are not uniformly distributed across populations. Instead, certain work environments can amplify exposure frequency or intensity, necessitating targeted risk management strategies. This shift reframes the discussion from passive patient education to active hazard identification in professional contexts, where cumulative or repeated contact with pharmaceutical agents may elevate risk profiles beyond those observed in general clinical use.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health and science information, we now focus specifically on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves necrosis of the jawbone and can occur spontaneously, though it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The scientific evidence connecting Fosamax to ONJ is grounded in clinical reports, pharmacological understanding, and mechanistic studies.

Clinical Presentation and Diagnosis of ONJ

Clinical presentation and diagnosis of ONJ typically involve exposed necrotic bone in the maxillofacial region that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, often following dental procedures. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Pharmacological Mechanisms and Animal Model Evidence

Fosamax pharmacology involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mass and reducing fracture risk in osteoporosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), it may also contribute to ONJ development. Mechanistic pathways linking Fosamax to ONJ are supported by multiscale characterization of jawbone in animal models. Research using estrogen-deficient rats treated with bisphosphonate (alendronate) has shown effects on the jawbone, including changes in tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings provide comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high remodeling rate and susceptibility to bisphosphonate accumulation may explain its vulnerability to necrosis.

Risk Considerations and Causation for Affected Patients

Risk considerations for affected patients include the adequacy of warnings regarding Fosamax and ONJ. The prescribing information includes a warning that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term exposure may increase ONJ risk, though individual patient factors also play a role. Causation-related considerations for affected patients involve the timeline between exposure and documented harm. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This indicates that while ONJ is a recognized adverse effect, its incidence in clinical trials was not significantly different from placebo, suggesting that other factors, such as dental procedures or comorbidities, may be necessary triggers.

Summary of Scientific Evidence

In summary, the scientific evidence establishes a connection between Fosamax and ONJ through clinical reports, pharmacological mechanisms, and animal model studies. The risk is influenced by duration of exposure, dental procedures, and patient-specific factors. Adequate warnings are provided in the prescribing information, but patients and healthcare providers should be aware of the potential for ONJ, especially with long-term use and invasive dental treatments.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The evidence includes clinical reports of ONJ in patients taking Fosamax, pharmacological mechanisms involving inhibition of bone resorption, and animal model studies showing jawbone changes. The prescribing information warns of ONJ risk, and risk factors include invasive dental procedures and long-term use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://pubmed.ncbi.nlm.nih.gov/40345077/)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How should patients on Fosamax manage dental procedures to reduce ONJ risk?

Patients requiring invasive dental procedures may consider discontinuing bisphosphonate treatment to reduce ONJ risk, as per prescribing information. However, the optimal duration of use is not determined, and for low-risk patients, drug discontinuation after 3-5 years is considered. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.